memo - Magazine of European Medical Oncology

memo - Magazine of European Medical Oncology OnlineFirst articles

20.02.2020 | short review Open Access

The role of pathology in sarcoma

Soft tissue sarcomas are exceedingly rare cancers with more than 100 different histiologic subtypes and tremendous morphologic heterogeneity. Next generation sequencing (NGS) techniques have drastically improved our knowledge about these tumours.

PDF-Version jetzt herunterladen Zum Volltext

20.02.2020 | special report Open Access

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome …

PDF-Version jetzt herunterladen Zum Volltext

17.02.2020 | short review Open Access

Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment

The introduction of checkpoint inhibitors (CPI) has set a paradigm shift within the therapies for a variety of advanced solid tumors. By altering key regulators of cellular immune response, so-called immune checkpoints, CPIs modulate peripheral …

PDF-Version jetzt herunterladen Zum Volltext

06.02.2020 | short review Open Access

Molecular profiling in breast cancer—ready for clinical routine?

The herald of genomic testing opened novel diagnostic and therapeutic possibilities for many tumor entities. For breast cancer, molecular profiling has become an integral part of disease management on multiple levels. Genetic testing allows for …

PDF-Version jetzt herunterladen Zum Volltext

05.02.2020 | short review Open Access

AML—is it time to drive a CAR(-T)?

The treatment options for newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) have substantially improved over the last 5 years. However, even though novel targeted agents (e.g. venetoclax, IDH1/2 and novel FLT-3 inhibitors; …

PDF-Version jetzt herunterladen Zum Volltext

Weitere Informationen

Titel

memo - Magazine of European Medical Oncology

Verlag

Springer Vienna

Abdeckung

Volume 1/2008 - Volume 13/2020

Print ISSN

1865-5041

Elektronische ISSN

1865-5076

DOI

https://doi.org/10.1007/12254.1865-5076

Schlagwörter

Onkologie und Hämatologie

Zeitschriften-ID

12254